A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 68,600 shares of ELYM stock, worth $281,946. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,600
Previous 37,000 85.41%
Holding current value
$281,946
Previous $263,000 32.7%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.98 - $8.93 $157,368 - $282,188
31,600 Added 85.41%
68,600 $349,000
Q2 2024

Aug 09, 2024

BUY
$2.6 - $10.2 $68,595 - $269,106
26,383 Added 248.5%
37,000 $263,000
Q1 2024

May 13, 2024

BUY
$2.54 - $2.98 $35 - $41
14 Added 0.13%
10,617 $29,000
Q4 2023

Feb 13, 2024

BUY
$2.45 - $2.85 $25,977 - $30,218
10,603 New
10,603 $29,000

Others Institutions Holding ELYM

About Eliem Therapeutics, Inc.


  • Ticker ELYM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,567,700
  • Market Cap $109M
  • Description
  • Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...
More about ELYM
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.